Long-term vancomycin shows promise in preventing recurrent C. diff infections

For patients battling recurrent C. diff who can't access fecal microbiota transplants (FMT), long-term vancomycin suppression may be a meaningful alternative. A retrospective study of Veterans Health Administration data found that among 324 patients on suppressive vancomycin, none developed CDI during therapy — and the risk of recurrence after stopping treatment was 71% lower compared to a vancomycin taper regimen.

Importantly, the therapy didn't come with a major safety red flag: only 2.8% of suppression patients developed vancomycin-resistant Enterococcus (VRE) cultures, compared to 3.7% in the taper group. Longer duration also mattered — patients on suppression for more than 6 months fared significantly better than those on it for 3–6 months.

By the Numbers:

• 324 patients on suppressive vancomycin; 0 developed CDI during therapy
• 71% lower CDI recurrence risk vs. vancomycin taper (HR 0.29)
• 2.8% VRE rate in suppression group vs. 3.7% in taper group
• Median vancomycin duration: 510 days
• Up to 50% recurrence risk after multiple CDI episodes

Why it matters: Recurrent CDI is a serious and growing clinical challenge, with recurrence risk climbing after each episode. For patients who aren't FMT candidates — due to antibiotic use, limited life expectancy, or lack of access — suppressive vancomycin could fill a critical gap in care.